vs

Side-by-side financial comparison of CHAIN BRIDGE BANCORP INC (CBNA) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

CHAIN BRIDGE BANCORP INC is the larger business by last-quarter revenue ($14.7M vs $12.5M, roughly 1.2× Avidity Biosciences, Inc.). CHAIN BRIDGE BANCORP INC runs the higher net margin — 36.4% vs -1398.3%, a 1434.7% gap on every dollar of revenue. CHAIN BRIDGE BANCORP INC produced more free cash flow last quarter ($11.5M vs $-156.9M).

Suburban Bancorp, Inc. was a publicly traded multibank holding company headquartered in suburban Chicago. It was founded by Gerald F. Fitzgerald, father of former U.S. Senator Peter Fitzgerald, and majority owned by the Fitzgerald family. Bank of Montreal acquired Suburban Bancorp, Inc. by merger in 1994. Harris Bankmont, Inc., an American subsidiary of Bank of Montreal, merged with Suburban Bankcorp to expand the Harris Bank presence in the Chicago area. The all-stock deal was valued at $246...

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CBNA vs RNA — Head-to-Head

Bigger by revenue
CBNA
CBNA
1.2× larger
CBNA
$14.7M
$12.5M
RNA
Higher net margin
CBNA
CBNA
1434.7% more per $
CBNA
36.4%
-1398.3%
RNA
More free cash flow
CBNA
CBNA
$168.4M more FCF
CBNA
$11.5M
$-156.9M
RNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CBNA
CBNA
RNA
RNA
Revenue
$14.7M
$12.5M
Net Profit
$5.3M
$-174.4M
Gross Margin
Operating Margin
45.6%
-1513.5%
Net Margin
36.4%
-1398.3%
Revenue YoY
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$0.81
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBNA
CBNA
RNA
RNA
Q4 25
$14.7M
Q3 25
$13.1M
$12.5M
Q2 25
$12.6M
$3.8M
Q1 25
$14.5M
$1.6M
Q4 24
$3.0M
Q3 24
$16.7M
$2.3M
Q2 24
$2.0M
Q1 24
$3.5M
Net Profit
CBNA
CBNA
RNA
RNA
Q4 25
$5.3M
Q3 25
$4.7M
$-174.4M
Q2 25
$4.6M
$-157.3M
Q1 25
$5.6M
$-115.8M
Q4 24
$-102.3M
Q3 24
$7.5M
$-80.4M
Q2 24
$-70.8M
Q1 24
$-68.9M
Operating Margin
CBNA
CBNA
RNA
RNA
Q4 25
45.6%
Q3 25
44.9%
-1513.5%
Q2 25
45.8%
-4448.7%
Q1 25
48.4%
-8360.9%
Q4 24
-4069.6%
Q3 24
56.3%
-4200.9%
Q2 24
-4040.4%
Q1 24
-2178.6%
Net Margin
CBNA
CBNA
RNA
RNA
Q4 25
36.4%
Q3 25
35.8%
-1398.3%
Q2 25
36.3%
-4089.3%
Q1 25
38.6%
-7360.0%
Q4 24
-3439.5%
Q3 24
44.8%
-3441.7%
Q2 24
-3461.8%
Q1 24
-1943.4%
EPS (diluted)
CBNA
CBNA
RNA
RNA
Q4 25
$0.81
Q3 25
$0.72
$-1.27
Q2 25
$0.70
$-1.21
Q1 25
$0.85
$-0.90
Q4 24
$-0.80
Q3 24
$1.64
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBNA
CBNA
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$586.6M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$169.2M
$1.9B
Total Assets
$1.8B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBNA
CBNA
RNA
RNA
Q4 25
$586.6M
Q3 25
$395.7M
$350.2M
Q2 25
$377.3M
$243.9M
Q1 25
$629.2M
$254.2M
Q4 24
$219.9M
Q3 24
$639.8M
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
CBNA
CBNA
RNA
RNA
Q4 25
$169.2M
Q3 25
$163.1M
$1.9B
Q2 25
$156.9M
$1.2B
Q1 25
$151.5M
$1.3B
Q4 24
$1.4B
Q3 24
$104.8M
$1.5B
Q2 24
$1.2B
Q1 24
$830.9M
Total Assets
CBNA
CBNA
RNA
RNA
Q4 25
$1.8B
Q3 25
$1.5B
$2.1B
Q2 25
$1.4B
$1.4B
Q1 25
$1.7B
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
$1.6B
Q2 24
$1.3B
Q1 24
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBNA
CBNA
RNA
RNA
Operating Cash FlowLast quarter
$15.6M
$-156.2M
Free Cash FlowOCF − Capex
$11.5M
$-156.9M
FCF MarginFCF / Revenue
78.1%
-1257.6%
Capex IntensityCapex / Revenue
28.0%
5.7%
Cash ConversionOCF / Net Profit
2.92×
TTM Free Cash FlowTrailing 4 quarters
$17.9M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBNA
CBNA
RNA
RNA
Q4 25
$15.6M
Q3 25
$2.8M
$-156.2M
Q2 25
$3.4M
$-199.7M
Q1 25
$3.1M
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Free Cash Flow
CBNA
CBNA
RNA
RNA
Q4 25
$11.5M
Q3 25
$2.5M
$-156.9M
Q2 25
$2.5M
$-203.0M
Q1 25
$1.4M
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
CBNA
CBNA
RNA
RNA
Q4 25
78.1%
Q3 25
18.7%
-1257.6%
Q2 25
20.0%
-5277.1%
Q1 25
9.8%
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
CBNA
CBNA
RNA
RNA
Q4 25
28.0%
Q3 25
2.5%
5.7%
Q2 25
6.5%
86.9%
Q1 25
11.6%
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
CBNA
CBNA
RNA
RNA
Q4 25
2.92×
Q3 25
0.59×
Q2 25
0.73×
Q1 25
0.55×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons